These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

751 related items for PubMed ID: 25559461

  • 1. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
    Borowczyk M, Wojtaszewska M, Lewandowski K, Gil L, Lewandowska M, Lehmann-Kopydłowska A, Kroll-Balcerzak R, Balcerzak A, Iwoła M, Michalak M, Komarnicki M.
    Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Usefulness of real-time semi-quantitative PCR, JAK2 MutaScreen kit for JAK2 V617F screening].
    Chae H, Lee JH, Lim J, Jung SW, Kim M, Kim Y, Han K, Cho BS, Cho SG, Lee JW, Min WS.
    Korean J Lab Med; 2009 Jun; 29(3):243-8. PubMed ID: 19571623
    [Abstract] [Full Text] [Related]

  • 6. The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms.
    Trifa AP, Cucuianu A, Petrov L, Urian L, Militaru MS, Dima D, Pop IV, Popp RA.
    Ann Hematol; 2010 Oct; 89(10):979-83. PubMed ID: 20422415
    [Abstract] [Full Text] [Related]

  • 7. Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR.
    Kinz E, Leiherer A, Lang AH, Drexel H, Muendlein A.
    Int J Lab Hematol; 2015 Apr; 37(2):217-24. PubMed ID: 24963593
    [Abstract] [Full Text] [Related]

  • 8. Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms.
    Benati M, Montagnana M, Danese E, De Matteis G, Veneri D, Paviati E, Guidi GC.
    Clin Chem Lab Med; 2015 Jun; 53(7):1005-11. PubMed ID: 25527813
    [Abstract] [Full Text] [Related]

  • 9. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
    Medinger M, Skoda R, Gratwohl A, Theocharides A, Buser A, Heim D, Dirnhofer S, Tichelli A, Tzankov A.
    Br J Haematol; 2009 Jul; 146(2):150-7. PubMed ID: 19466975
    [Abstract] [Full Text] [Related]

  • 10. [Clinical significance of the quantification of JAK2V617F allele burden in classical Ph-negative myeloproliferative neoplasms].
    Kerguelén Fuentes AE, Hernández-Maraver D, Lombardia L, Canales Albendea MA, Rodriguez de la Rúa A.
    Med Clin (Barc); 2012 Oct 13; 139(9):373-8. PubMed ID: 22743278
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation.
    Bang SM, Lee JS, Ahn JY, Lee JH, Hyun MS, Kim BS, Park MR, Chi HS, Kim HY, Kim HJ, Lee MH, Kim H, Won JH, Yoon HJ, Oh DY, Nam EM, Bae SH, Kim BK, Korean MPN Working Party.
    Thromb Haemost; 2009 Mar 13; 101(3):547-51. PubMed ID: 19277418
    [Abstract] [Full Text] [Related]

  • 13. Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms.
    Fontanelli G, Baratè C, Ciabatti E, Guerrini F, Grassi S, Del Re M, Morganti R, Petrini I, Arici R, Barsotti S, Metelli MR, Danesi R, Galimberti S.
    Int J Lab Hematol; 2015 Dec 13; 37(6):766-73. PubMed ID: 26189968
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. JAK2 V617F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil.
    da Silva RR, Domingues Hatzlhofer BL, Machado CG, Lima AS, de Albuquerque DM, dos Santos MN, Fertrin KY, Costa FF, Araújo Ada S, Bezerra MA.
    Genet Test Mol Biomarkers; 2012 Jul 13; 16(7):802-5. PubMed ID: 22304488
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
    Duletić AN, Dekanić A, Hadzisejdić I, Kusen I, Matusan-Ilijas K, Grohovac D, Grahovac B, Jonjić N.
    Coll Antropol; 2012 Sep 13; 36(3):859-65. PubMed ID: 23213945
    [Abstract] [Full Text] [Related]

  • 18. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.
    Ha JS, Kim YK, Jung SI, Jung HR, Chung IS.
    Ann Lab Med; 2012 Nov 13; 32(6):385-91. PubMed ID: 23130336
    [Abstract] [Full Text] [Related]

  • 19. High Risk Janus Kinase 2 V617F Allele Burden in a Seven-Year Cohort of Patients with Myeloproliferative Neoplasms.
    Chatambudza M, Skhosana L, Ketseoglou I, Wiggill T.
    Clin Lab; 2021 Nov 01; 67(11):. PubMed ID: 34758219
    [Abstract] [Full Text] [Related]

  • 20. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
    Payzin KB, Savasoglu K, Alacacioglu I, Ozdemirkiran F, Mutlu BB, Bener S, Calli AO, Kucukzeybek BB, Aksun S.
    Clin Lymphoma Myeloma Leuk; 2014 Dec 01; 14(6):525-33. PubMed ID: 24811089
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.